# PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

> **NCT03166085** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** PU-H71
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT03166085
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2021-12-14
- **Final completion:** 2021-12-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166085, "PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03166085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*